TNGX 株価分析 — TANGO THERAPEUTICS INC (Healthcare >> Biotechnology)
TNGX に関するよくある質問
TNGXのPER(株価収益率)は?
TANGO THERAPEUTICS INC(TNGX)は現在PER 282.60倍で取引されています。
TNGXのROE(自己資本利益率)は?
TANGO THERAPEUTICS INCのROEは-27.39%です。
TNGXの配当利回りは?
TANGO THERAPEUTICS INCの配当利回りは0.00%です。
TNGXの品質スコア(Quality Score)は?
当社のAIはTNGXの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
TNGXは今が買い時ですか?
当社AIのタイミングスコアは100点中67点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
TNGXはどのセクターに属しますか?
TANGO THERAPEUTICS INCはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
TNGX AI Analysis Summary
Our AI summary for TNGX: TANGO THERAPEUTICS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 282.60, ROE of -27.39%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 27.18
Price
-0.39
(-1.41%)
Day Change
|
|
|---|
TNGX, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 81 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 27.18 |
| PBV / Sector |
11.47 / 5.20
|
| Earning Per Share | -0.65 |
| PE / Sector |
282.60 / 19.97
|
| PEG or PE/Growth / Sector |
-29.78 / 1.22
|
| Average 1M Daily Value |
64.59 M
|
| Average 1W Daily Value |
49.67 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:35 |
| Symbol | TNGX |
| Name | TANGO THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 162.81 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4,488.80 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 201 Brookline Avenue, Boston, MA, United States, 02215
Phone: 857 320 4900
Website: https://www.tangotx.com
Employees: 137
Sector: Healthcare >> Biotechnology
Description: Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google